Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Equity Average (2016 - 2025)

Historic Equity Average for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $2.7 billion.

  • Dexcom's Equity Average rose 3406.75% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 billion, marking a year-over-year increase of 3406.75%. This contributed to the annual value of $2.4 billion for FY2025, which is 1623.99% up from last year.
  • Per Dexcom's latest filing, its Equity Average stood at $2.7 billion for Q4 2025, which was up 3406.75% from $2.6 billion recorded in Q3 2025.
  • In the past 5 years, Dexcom's Equity Average ranged from a high of $2.7 billion in Q4 2025 and a low of $1.6 billion during Q1 2021
  • Over the past 5 years, Dexcom's median Equity Average value was $2.2 billion (recorded in 2023), while the average stood at $2.1 billion.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 7592.32% in 2021, then plummeted by 587.8% in 2024.
  • Over the past 5 years, Dexcom's Equity Average (Quarter) stood at $2.0 billion in 2021, then grew by 0.06% to $2.0 billion in 2022, then increased by 9.61% to $2.2 billion in 2023, then decreased by 5.88% to $2.0 billion in 2024, then skyrocketed by 34.07% to $2.7 billion in 2025.
  • Its last three reported values are $2.7 billion in Q4 2025, $2.6 billion for Q3 2025, and $2.4 billion during Q2 2025.